FilingReader Intelligence
Kelun Pharma prioritizes innovation, rewards shareholders, and boosts financial health
April 23, 2025 at 05:46 PM UTC•By FilingReader AI
** Sichuan Kelun Pharmaceutical (SZSE:002422) is prioritizing innovation, shareholder value, and strategic financial management, as highlighted in its 2024 Annual Report Summary and related announcements. The company’s Board recommends a cash dividend of CNY 5.03 per 10 shares, totaling CNY 800.16 million, showcasing its commitment to returns.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
2024 Annual Audit ReportApril 23, 2025 at 12:25 PM UTC
2024 Annual ReportApril 23, 2025 at 12:25 PM UTC
Announcement on the Company and its subsidiaries' hedging businessApril 23, 2025 at 12:25 PM UTC
Announcement on Changes in the Company's Accounting PoliciesApril 23, 2025 at 12:25 PM UTC
Announcement on Using Own Funds to Purchase Financial ProductsApril 23, 2025 at 12:25 PM UTC
Announcement on the 2024 Profit Distribution PlanApril 23, 2025 at 12:25 PM UTC
Announcement on Early Termination of 2021 Employee Stock Ownership PlanApril 23, 2025 at 12:25 PM UTC
Annual report on the use of raised fundsApril 23, 2025 at 12:25 PM UTC
Announcement on Early Termination of 2022 Employee Stock Ownership PlanApril 23, 2025 at 12:25 PM UTC
SZSE:002422•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Sichuan Kelun Pharmaceutical publishes news
Free account required • Unsubscribe anytime